Scientific Research

AAV vs. Bocavirus – gleich große Bereiche
Dr. Ning Meng — Development of a novel site-specific conjugation method on AAV capsid :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.1rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } }
Project Description

Massive studies on AAV capsid engineering have been done to create AAV vectors with desired transduction efficiency and specificity in target cells. Chemical conjugation of receptor-binding agents onto the AAV capsids holds potential to alter its tropism. The most commonly used engineering method, genetic insertion of short peptide, can lead to several problems including failure of expression and assembly of VP, changes in the binding affinity of the peptide, etc., due to the interaction between the inserted peptide and neighbouring amino acid residues in AAV capsid/virion protein (VP). Chemical conjugation after AAV production, on the other hand, has the benefit that it does not influence VP expression and assembly, while largely preserving the binding affinity of the peptide. Furthermore, chemical conjugation can introduce any kinds of molecules, including small molecules, peptides and proteins with complex structures, and aptamers.

The conventional conjugation relies on lysine residues. Owing to the abundance of surface-exposed lysine residues on the AAV capsid, this strategy lacks site specificity, which in turn leads to undesired modifications of functional lysine residues and a heterogenous mixture of particles with different conjugation patterns. In contrast, AAV capsid does not have any surface-exposed cysteine residues. In this study, I established and validated a workflow for a novel site-specific conjugation method by introducing a cysteine residue at the site of interest. Subsequent site-specific conjugation can be achieved between the thiol group (-SH) on the cysteine and any substrate that bears a maleimide group. Furthermore, the number of cysteines on the capsid can be simply controlled by producing mosaic capsids, which is achieved by mixing VP plasmids during production.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

GBM is a tumour in the brain and represents the most lethal intracranial tumour, because it is fast-growing, highly invasive and highly resistant to traditional radiotherapy and chemotherapy. Gene therapy has been developed for several cancers including GBM. Early research on AAV-mediated gene therapy for GBM used wild-type AAVs, but the low efficiency and specificity of transduction in GBM limited the therapeutic effects. In this study, I aimed to design AAV vectors with higher transduction efficiency and specificity in GBM. 

I have done study of this topic (11.2020-03.2024). The idea was to display both blood-brain-barrier (BBB)-penetrating peptide and tumour-targeting peptide on AAV capsid. During the study, I selected several BBB-penetrating and tumour-targeting peptides that bind to different receptors. But I encountered numerous challenges that inserting these peptides on the AAV capsid lead to unexpected impacts on the expression and assembly of the capsid protein as well as change of binding ability of the inserted peptide. In in vivo (mice) study, only display of an epiderma growth factor receptor (EGFR)-binding peptide FALGEA showed higher transduction in GBM than AAV9. However, later study discovered that FALGEA-displayed AAV did not bind to EGFR.  

Therefore, in this new round of study, I decided to use different methods to develop AAV vectors that bind to GBM receptors: (1) display of nanobody, (2) display of receptor binder via computational design (Bindcraft, Pacesa et. al, 2025), and (3) AAV library screening. For the GBM receptors, I narrowed down to EGFR, EGFR variant III (EGFRvIII) and Interleukin-13 receptor subunit alpha-2 (IL13Rα2). Overexpression of EGFR is a hallmark of most forms of GBM. Some GBM types also express the EGFRvIII mutant with a deletion of amino acid residues 6-273 in the extracellular domain, which is a tumor-specific marker. And IL13Rα2 is another receptor that is often overexpressed in GBM.  

In the recent years, more BBB penetrating AAV variants have been developed. I chose three variants that have been validated in both mice and non-human primates to combine with GBM receptor targeting: alkaline phosphatase (ALPL)-mediated VCAP-102, and low-density lipoprotein receptor-related protein 6 (LRP6)-mediated CAP-Mac and BI30.  

Jixin Liu — Engineering Adeno-Associated Virus (AAV) Capsid and Replication Proteins :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } }
Project Description

Delivery platforms of current gene therapy are generally categorized into viral and non-viral systems. Among viral vectors, Adeno-associated virus (AAV) is the leading platform due to its low immunogenicity, long-term gene expression and strong tissue specificity. In comparison, lipid nanoparticles (LNPs) have gained prominence as non-viral delivery systems due to their scalability and lower manufacturing costs.

Despite its advantages, AAV-based gene therapy faces two major challenges. First, although naturally occurring AAV exhibits tissue tropism, achieving high specificity and efficient targeting for certain tissues remains suboptimal. Second, AAV production is costly and labor-intensive, significantly limiting the accessibility of AAV-based therapies for a broader patient population compared to LNP-based gene therapy.

At the start of this project, existing research had already demonstrated the feasibility of capsid engineering to alter AAV tropism and improve delivery efficiency. Similarly, replication (Rep) proteins were known to play a critical role in viral genome replication and packaging, yet systematic engineering of Rep proteins to enhance production yield remained underexplored. Additionally, advances in high-throughput screening and sequencing technologies opened opportunities for large-scale variant evaluation, though analytical challenges such as sequencing bias and duplicate variant detection persisted.

Based on these gaps, this project is driven by two primary objectives:

  • To enhance AAV tissue specificity through capsid engineering, with a focus on CNS, muscle, heart, and glioblastoma targeting.
  • To improve AAV production efficiency by engineering replication proteins, thereby reducing manufacturing costs.

The hypothesis is that combining high-diversity library generation, barcoded screening, and computational analysis will enable the identification of optimized capsid and Rep variants with superior functional properties.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

Delivery platforms of current gene therapy are generally categorized into viral and non-viral systems. Among viral vectors, Adeno-associated virus (AAV) is the leading platform due to its low immunogenicity, long-term gene expression and strong tissue specificity. In comparison, lipid nanoparticles (LNPs) have gained prominence as non-viral delivery systems due to their scalability and lower manufacturing costs. 

Despite its advantages, AAV-based gene therapy faces two major challenges. First, although naturally occurring AAV exhibits tissue tropism, achieving high specificity and efficient targeting for certain tissues remains suboptimal. Second, AAV production is costly and labor-intensive, significantly limiting the accessibility of AAV-based therapies for a broader patient population compared to LNP-based gene therapy. 

At the start of this project, existing research had already demonstrated the feasibility of capsid engineering to alter AAV tropism and improve delivery efficiency. Similarly, replication (Rep) proteins were known to play a critical role in viral genome replication and packaging, yet systematic engineering of Rep proteins to enhance production yield remained underexplored. Additionally, advances in high-throughput screening and sequencing technologies opened opportunities for large-scale variant evaluation, though analytical challenges such as sequencing bias and duplicate variant detection persisted. 

 Based on these gaps, this project is driven by two primary objectives: 

  • To enhance AAV tissue specificity through capsid engineering, with a focus on CNS, muscle, heart, and glioblastoma targeting. 
  • To improve AAV production efficiency by engineering replication proteins, thereby reducing manufacturing costs. 

 The hypothesis is that combining high-diversity library generation, barcoded screening, and computational analysis will enable the identification of optimized capsid and Rep variants with superior functional properties. 

Sabrina Weis — ConCap-Seq :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Efficient and specific gene delivery remains a central challenge in AAV-based gene therapy. While AAV vectors have achieved clinical success, naturally occurring serotypes often fail to target defined human cell types, necessitating high doses that increase the risk of adverse effects. As the capsid dictates cell tropism, AAV capsid engineering continues to be a critical strategy for improving vector performance. One established strategy involves the diversification of the capsid gene through DNA family shuffling. This process generates millions of chimeric capsid (cap) genes, which are then subjected to directed evolution to enrich variants with desired properties. However, analyzing these enriched cap sequences and identifying the most promising candidates requires advanced sequencing techniques.

DNA shuffling modifies the entire cap gene, making it essential to employ long-read sequencing platforms for analysis. Among available options, Oxford Nanopore Technologies (ONT) sequencing offers a cost-effective alternative but its higher error rate complicates the resolution of individual variants required for precise capsid library analysis. PacBio’s single-molecule real-time (SMRT) sequencing, particularly in its circular consensus sequencing (CCS) mode, provides highly accurate long reads suitable for downstream analyses but has the downside of lower throughput compared to next-generation sequencing (NGS) techniques.

For CCS sequencing, target DNA is ligated to single-stranded hairpin adapters (SMRTbells), enabling the polymerase to pass both strands of the circularized template multiple times during sequencing. Consensus sequences from these noisy subreads achieve high accuracy as randomly distributed sequencing errors average out. Read accuracy thus depends on polymerase pass number, constrained by the overall polymerase read length. The Sequel IIe achieves an N50 read length of ~150 kb and requires ~10 polymerase passes to reach a Phred score 30. Beyond this threshold, additional passes yield only marginal improvements. Consequently, optimal SMRTbell insert sizes are ~15 kb to fully exploit the potential of the sequencing platform. Since the cap gene spans only 2.2 kb, concatenating multiple cap genes offers a promising strategy to substantially enhance throughput over single-cap-gene sequencing.

Concatenation-based strategies have previously been applied to SMRT sequencing of shorter genes, most notably in the context of RNA isoform sequencing. Here, we introduce ConCap-Seq, a USER fusion-based concatenation approach similar to MAS-Iso-Seq, optimized for highly diverse AAV cap libraries. ConCap-Seq streamlines concatenation and SMRTbell adapter ligation in a single reaction, enabling precise control over concatemer length to optimize throughput and specificity. We benchmark ConCap-Seq against standard single-gene SMRT-CCS sequencing to evaluate throughput and read quality, while spike-in controls validate quantitative accuracy, essential for tracking variant enrichment during directed evolution.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

Efficient and specific gene delivery remains a central challenge in AAV-based gene therapy. While AAV vectors have achieved clinical success, naturally occurring serotypes often fail to target defined human cell types, necessitating high doses that increase the risk of adverse effects. As the capsid dictates cell tropism, AAV capsid engineering continues to be a critical strategy for improving vector performance. One established strategy involves the diversification of the capsid gene through DNA family shuffling. This process generates millions of chimeric capsid (cap) genes, which are then subjected to directed evolution to enrich variants with desired properties. However, analyzing these enriched cap sequences and identifying the most promising candidates requires advanced sequencing techniques. 

DNA shuffling modifies the entire cap gene, making it essential to employ long-read sequencing platforms for analysis. Among available options, Oxford Nanopore Technologies (ONT) sequencing offers a cost-effective alternative but its higher error rate complicates the resolution of individual variants required for precise capsid library analysis. PacBio’s single-molecule real-time (SMRT) sequencing, particularly in its circular consensus sequencing (CCS) mode, provides highly accurate long reads suitable for downstream analyses but has the downside of lower throughput compared to next-generation sequencing (NGS) techniques.  

For CCS sequencing, target DNA is ligated to single-stranded hairpin adapters (SMRTbells), enabling the polymerase to pass both strands of the circularized template multiple times during sequencing. Consensus sequences from these noisy subreads achieve high accuracy as randomly distributed sequencing errors average out. Read accuracy thus depends on polymerase pass number, constrained by the overall polymerase read length. The Sequel IIe achieves an N50 read length of ~150 kb and requires ~10 polymerase passes to reach a Phred score 30. Beyond this threshold, additional passes yield only marginal improvements. Consequently, optimal SMRTbell insert sizes are ~15 kb to fully exploit the potential of the sequencing platform. Since the cap gene spans only 2.2 kb, concatenating multiple cap genes offers a promising strategy to substantially enhance throughput over single-cap-gene sequencing.  

Concatenation-based strategies have previously been applied to SMRT sequencing of shorter genes, most notably in the context of RNA isoform sequencing. Here, we introduce ConCap-Seq, a USER fusion-based concatenation approach similar to MAS-Iso-Seq, optimized for highly diverse AAV cap libraries. ConCap-Seq streamlines concatenation and SMRTbell adapter ligation in a single reaction, enabling precise control over concatemer length to optimize throughput and specificity. We benchmark ConCap-Seq against standard single-gene SMRT-CCS sequencing to evaluate throughput and read quality, while spike-in controls validate quantitative accuracy, essential for tracking variant enrichment during directed evolution. 

Dr. Man XU — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Efficient and specific gene delivery remains a central challenge in AAV-based gene therapy. While AAV vectors have achieved clinical success, naturally occurring serotypes often fail to target defined human cell types, necessitating high doses that increase the risk of adverse effects. As the capsid dictates cell tropism, AAV capsid engineering continues to be a critical strategy for improving vector performance. One established strategy involves the diversification of the capsid gene through DNA family shuffling. This process generates millions of chimeric capsid (cap) genes, which are then subjected to directed evolution to enrich variants with desired properties. However, analyzing these enriched cap sequences and identifying the most promising candidates requires advanced sequencing techniques.

DNA shuffling modifies the entire cap gene, making it essential to employ long-read sequencing platforms for analysis. Among available options, Oxford Nanopore Technologies (ONT) sequencing offers a cost-effective alternative but its higher error rate complicates the resolution of individual variants required for precise capsid library analysis. PacBio’s single-molecule real-time (SMRT) sequencing, particularly in its circular consensus sequencing (CCS) mode, provides highly accurate long reads suitable for downstream analyses but has the downside of lower throughput compared to next-generation sequencing (NGS) techniques.

For CCS sequencing, target DNA is ligated to single-stranded hairpin adapters (SMRTbells), enabling the polymerase to pass both strands of the circularized template multiple times during sequencing. Consensus sequences from these noisy subreads achieve high accuracy as randomly distributed sequencing errors average out. Read accuracy thus depends on polymerase pass number, constrained by the overall polymerase read length. The Sequel IIe achieves an N50 read length of ~150 kb and requires ~10 polymerase passes to reach a Phred score 30. Beyond this threshold, additional passes yield only marginal improvements. Consequently, optimal SMRTbell insert sizes are ~15 kb to fully exploit the potential of the sequencing platform. Since the cap gene spans only 2.2 kb, concatenating multiple cap genes offers a promising strategy to substantially enhance throughput over single-cap-gene sequencing.

Concatenation-based strategies have previously been applied to SMRT sequencing of shorter genes, most notably in the context of RNA isoform sequencing. Here, we introduce ConCap-Seq, a USER fusion-based concatenation approach similar to MAS-Iso-Seq, optimized for highly diverse AAV cap libraries. ConCap-Seq streamlines concatenation and SMRTbell adapter ligation in a single reaction, enabling precise control over concatemer length to optimize throughput and specificity. We benchmark ConCap-Seq against standard single-gene SMRT-CCS sequencing to evaluate throughput and read quality, while spike-in controls validate quantitative accuracy, essential for tracking variant enrichment during directed evolution.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

Cancer immunotherapy has gained remarkable success in several B‑cell malignancies. To date, seven CAR‑T products have received FDA approval, with hundreds more in clinical stage. Most of these therapies rely on retroviral vectors for delivery of the therapeutic CAR payload. However, retroviral systems are primarily designed for ex vivo engineering show several limitations, including integration‑related mutagenesis, complexity in therapy procedures. 

Adeno‑associated virus (AAV) vectors offer distinct advantages over existing viral platforms, which may circumvent these problems. AAVs exhibit long persistence, a non‑integrating vector, a well‑established clinical safety profile, and the ability to achieve  tissue specific tropism through capsid engineering. Several recent studies have demonstrated the feasibility of using AAV to deliver CAR constructs to primary human T cells, often in combination with electroporation or lipid nanoparticles for CRISPR–Cas protein delivery. These studies prove that AAV‑mediated T‑cell engineering is technically achievable. 

Our project aims to evaluate whether AAV can function as a single vector system capable of delivering both the CRISPR–Cas machinery and the CAR/TCR payload. If successful, this strategy would be used in the next step in vivo T‑cell engineering – an area of great interest across the immunotherapy field.  

Dr. Jan BIERI — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

My research addresses the lack of AAVs that specifically target and transduce proerythroblasts. Two main strategies are being pursued in order to create such a vector. One is the modification of the capsid surface with the receptor-binding domain (RBD) of parvovirus B19 (B19V), which allows efficient uptake into proerythroblasts. Importantly, the RBD of B19V binds to a currently unknown receptor that is only found on proerythroblast and trophoblast cells. The second strategy focuses on the optimization of specific promoters that display uniquely high activities in erythroid cells.

Cells of the erythroid lineage represent a biologically important but largely inaccessible target for AAV-based gene delivery. To date, no AAV vectors have been described which selectively transduce committed erythroid progenitor cells. Importantly, erythroid progenitors are distinct from hematopoietic stem cells and are characterized by limited self-renewal capacity and defined differentiation trajectories. Consequently, strategies aimed at erythroid progenitors are not suited for permanent stem cell correction but may be relevant for applications requiring lineage-restricted, stage-specific, or transient genetic manipulation. In this context, achieving high specificity with minimal off-target transduction is particularly critical. As an example, AAV6 provides the greatest transduction efficiency in hematopoietic cells among all known serotypes. However, AAV6 also displays high efficiency in a broad spectrum of other cell lines and tissue types.

Taken together, this leaves many serious and potentially life-threatening erythroid disorders without an efficient cure, such as Diamond-Blackfan anemia, thalassemias, GATA1 deficiency, erythroleukemia, and X-linked sideroblastic anemia.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

My research addresses the lack of AAVs that specifically target and transduce proerythroblasts.
Two main strategies are being pursued in order to create such a vector. One is the modification
of the capsid surface with the receptor-binding domain (RBD) of parvovirus B19 (B19V) which
allows efficient uptake into proerythroblast. Importantly, the RBD of B19V binds to a currently
unknown receptor that is only found on proerythroblast and trophoblast cells. The second strategy
focuses on the optimization of specific promoters that displays uniquely high activites in erythroid
cells.
Cells of the erythroid lineage represent a biologically important but largely inaccessible target for
AAV-based gene delivery. To date, no AAV vectors have been described which selectively
transduce committed erythroid progenitor cells. Importantly, erythroid progenitors are distinct from
hematopoietic stem cells and are characterized by limited self-renewal capacity and defined
differentiation trajectories. Consequently, strategies aimed at erythroid progenitors are not suited
for permanent stem cell correction but may be relevant for applications requiring lineage-
restricted, stage-specific, or transient genetic manipulation. In this context, achieving high
specificity with minimal off-target transduction is particularly critical. As an example, AAV6
provides the greatest transduction efficiency in hematopoietic cells among all known serotypes.
However, AAV6 also displays high efficiency in an broad spectrum of other cell lines and tissue
types.
Taken together, this leaves many serious and potentially life-threatening erythroid disorders
without an efficient cure, such as Diamond-Blackfan anemia, thalassemias, GATA1 deficiency,
erythroleukemia, and X-linked sideroblastic anemia.

Yumi SANO — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Adeno-associated virus (AAV) is the leading viral vector for gene therapy, but it also faces important limitations, including a small packaging capacity (4.7 kb), the need for high doses, and the risk of off-target transduction. The current strategy to overcome the packaging limit is largely inefficient and costly as it requires efficient transduction of multiple AAV vectors carrying smaller gene fragments into the same cell. An alternative strategy is the use of hybrid vectors in which a recombinant AAV (rAAV) genome is packaged into another viral capsid. A notable example is the rAAV2 genome packaged in a human bocavirus 1 (HBoV1) capsid. HBoV1 is a mildly pathogenic respiratory virus that is reported to be able to cross package rAAV genome and deliver genes in primary human airway epithelial cells as well as human lung xenografted in mice and ferret lung in vivo. Importantly, HBoV1 can package up to 6.1 kb, overcoming AAV’s 4.7 kb limit and enabling applications such as base editing or delivery of cystic fibrosis treatment gene into airway epithelia. Nevertheless, bocaviruses face the same challenge as AAV of low transduction efficiency, necessitating high vector doses and supplementation of doxorubicin, which is both topoisomerase II inhibitor and proteasome inhibitor, to enhance the transduction of the virus. In particular, bocaviruses transduce cell lines inefficiently, hampering basic study of the virus such as the interactions with host cell factors or intracellular trafficking pathways. Therefore, I decided to employ capsid engineering techniques to improve the transduction of bocaviruses. Specifically, I explored point mutations to modify post-translational modifications, peptide insertions to grant the virus new or stronger binding to a receptor, as well as domain swapping between different serotypes of bocaviruses. In this study, HBoV1 and Gorilla bocavirus 1 (GBoV1) were used because HBoV1 is the most well-characterized virus of all bocaviruses, and because GBoV1 is one of the most superior transducer for many cell lines as well as various primary cells (except primary human airway epithelial cells that are transduced best by HBoV1).

In addition, since this virus has only been discovered in 2005 and most reports on the virus are on epidemiology, there are countless knowledge gap in bocavirus compared to AAV. Therefore, I have also investigated physicochemical property of the virus such as the optimal temperature to be stored, optimal buffer to be stored, change in its properties over time or over several freeze and thaw with the help of my student Linda. Some optimization of protocols in term of production, purification and transduction was also made as side projects.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

Adeno-associated virus (AAV) is the leading viral vector for gene therapy, but it also faces important limitations, including a small packaging capacity (4.7 kb), the need for high doses, and the risk of off-target transduction. The current strategy to overcome the packaging limit is largely inefficient and costly as it requires efficient transduction of multiple AAV vectors carrying smaller gene fragments into the same cell. An alternative strategy is the use of hybrid vectors in which a recombinant AAV (rAAV) genome is packaged into another viral capsid. A notable example is the rAAV2 genome packaged in a human bocavirus 1 (HBoV1) capsid. HBoV1 is a mildly pathogenic respiratory virus that is reported to be able to cross package rAAV genome and deliver genes in primary human airway epithelial cells as well as human lung xenografted in mice and ferret lung in vivo. Importantly, HBoV1 can package up to 6.1 kb, overcoming AAV’s 4.7 kb limit and enabling applications such as base editing or delivery of cystic fibrosis treatment gene into airway epithelia. Nevertheless, bocaviruses face the same challenge as AAV of low transduction efficiency, necessitating high vector doses and supplementation of doxorubicin, which is both topoisomerase II inhibitor and proteasome inhibitor, to enhance the transduction of the virus. In particular, bocaviruses transduce cell lines inefficiently, hampering basic study of the virus such as the interactions with host cell factors or intracellular trafficking pathways. Therefore, I decided to employ capsid engineering techniques to improve the transduction of bocaviruses. Specifically, I explored point mutations to modify post-translational modifications, peptide insertions to grant the virus new or stronger binding to a receptor, as well as domain swapping between different serotypes of bocaviruses. In this study, HBoV1 and Gorilla bocavirus 1 (GBoV1) were used because HBoV1 is the most well-characterized virus of all bocaviruses, and because GBoV1 is one of the most superior transducer for many cell lines as well as various primary cells (except primary human airway epithelial cells that are transduced best by HBoV1). 

In addition, since this virus has only been discovered in 2005 and most reports on the virus are on epidemiology, there are countless knowledge gap in bocavirus compared to AAV. Therefore, I have also investigated physicochemical property of the virus such as the optimal temperature to be stored, optimal buffer to be stored, change in its properties over time or over several freeze and thaw with the help of my student Linda. Some optimization of protocols in term of production, purification and transduction was also made as side projects. 

Dr. Felix BUBECK — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

To facilitate manipulation of the ITRs, we developed a pipeline for mutant AAV ITR screening, which ranges from a vector construct design allowing for easy modification of plasmid ITR sequences and a modified Sanger sequencing-based method for ITR integrity confirmation, to a barcode strategy to track the ITR variants during production and subsequent transduction. For this purpose, each ITR variant is associated with a specific DNA barcode in the 5′ UTR (untranslated region) of a transgene cassette on the vector genome. Upon ensuring integrity in the produced AAV, we tracked the ITR variants via the barcodes in episomal DNA and RNA, both in vitro and in vivo. While in human cells in vitro no ITR variant with improved function could be identified, in murine tissues several tested variants consistently exceeded the functionality of wtITRs. To supplement this work, we also devised a novel NGS pipeline to examine the integrative potential of the novel ITR variants by parallel interrogation of the integration region and the barcode sequence. The observed integration pattern matched the previously described preferential integration sites for rAAV.

Nanopore sequencing-based examination of the ITR integrity in vector genomes also revealed a previously undescribed trans-acting ITR-repair mechanism in which dominant ITR variants encoded in different plasmids can serve as repair templates. Nanopore sequencing of vectors produced with triple-barcoded conventional dual-ITR plasmids with alternative hairpin sequences confirmed the existence of both ITR cis- and trans-repair events. Our data indicate that trans-repair events depend on the position of mutations in the ITR, although major vector genome recombination events obscure the repair mechanism. The existence of ITR trans-repair was finally confirmed using vector genomes with low sequence identity which, in the absence of vector recombination, exhibited the exchange of ITR sequences. When engineering ITRs, it is essential that this novel repair mechanism be circumvented. This can be achieved by producing the ITR variants separately, permitting the generation of AAV vector libraries with an array of mutant ITRs that are stably maintained in the viral vector genome. However, library sizes on the scale of capsid variant screens remain currently unfeasible. The existence of the ITR trans-repair mechanism also has major implications for conventional AAV vector production. Due to these previously undescribed repair events, vector plasmid contaminations with damaged ITR sequences have little detrimental impact on ITR integrity and thereby product quality during AAV vector production.

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

To facilitate manipulation of the ITRs, we developed a pipeline for mutant AAV ITR screening, which ranges from a vector construct design allowing for easy modification of plasmid ITR sequences and a modified Sanger sequencing-based method for ITR integrity confirmation, to a barcode strategy to track the ITR variants during production and subsequent transduction. For this purpose, each ITR variant is associated with a specific DNA barcode in the 5‘ UTR (untranslated region) of a transgene cassette on the vector genome. Upon ensuring integrity in the produced AAV, we tracked the ITR variants via the barcodes in episomal DNA, RNA both in vitro and in vivo. While in human cells in vitro no ITR variant with improved function could be identified, in murine tissues several tested variants consistently exceed the wtITRs functionality. To supplement this work, we also devised a novel NGS pipeline to examine the integrative potential of the novel ITR variants by parallel interrogation of the integration region and the barcode sequence. The observed integration pattern matched the previously observed description of preferential integration sites for rAAV.   

Nanopore sequencing-based examination of the ITR integrity in vector genomes also revealed a previously undescribed trans-acting ITR-repair mechanism in which dominant ITR variants encoded in different plasmids can serve as repair template. Nanopore sequencing of vectors produced with triple-barcoded conventional dual ITR plasmids with alternative hairpin sequences confirmed the existence of both ITR cis- and trans-repair events. Our data indicates that trans-repair events depend on the position of mutations in the ITR, although major vector genome recombination events obscure the repair mechanism. The existence of ITR trans-repair was finally confirmed using vector genomes with low sequence identity which, in absence of vector recombination exhibited the exchange of ITR sequences. When engineering ITRs, it is essential that this novel repair mechanism is to be circumvented. This can be achieved by producing the ITR variants separately, permitting the generation AAV vector libraries with an array of mutant ITRs that are stably maintained in the viral vector genome. However, library sizes in the scale of capsid variant screens remain currently unfeasible. The existence of the ITR trans-repair mechanism also has major implications for the conventional AAV vector production. Due to these previously undescribed repair events, vector plasmid contaminations with damaged ITR sequences have little detrimental impact on ITR integrity and thereby product quality during AAV vector production. 

Dr. Sergio David MORENO-VELASQUEZ — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Evolutionäre Umgestaltung der Kapside bocaviraler Vektoren für die Gentherapie

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

The use of viral vectors to transport therapeutic genes has revolutionized medicine. Among all viruses with therapeutic potential, parvoviruses are particularly attractive candidates for the engineering of efficient gene delivery vectors. Bocaparvovirus (BoV) is a promising parvoviral alternative to the established Adeno-associated virus (AAV) for viral vector development due to an expanded cargo capacity.

Human bocaparvovirus 1 (HBoV1) can package an oversized rAAV genome of up to 5.8 kb and specifically transduces polarized human airway epithelia (pHAEs) in vitro, as well as the lungs of both newborn and juvenile ferrets. Previously, our lab has further expanded the prototype rAAV/HBoV1 vector system by exploring four additional primate-derived BoVs as templated for vector production, comprising three from humans (HBoV2-4) and one from Gorilla (GBoV). These chimeras can also package rAAV genomes of up to 6.1 kb, with rAAV/GBoV displaying the most extensive target range across various cell lines and primary cells. Despite these promising findings, we were unable to detect transgene expression in mice infected with either rAAV/HBoV1 or rAAV/GBoV1 carrying a gfp reporter gene (unpublished data). Collectively, the absence of transgene activity observed in vivo by other groups including our own underscores the critical need to create new BoV isolates with desired cell tropisms that can overcome the size limitations encounter in AAV-derived vectors in the use of large genes such as CRISPR-Cas9.

Directed evolution of capsid genes is a powerful strategy to increase viral fitness (e.g. new tropism, low immunoreactivity and greater efficiency) via iterative selection (biopanning). Previously, we have established the DNA family shuffling approach for AAV (i.e. production of chimeric capsids by homology-driven DNA recombination), enabling the creation of large libraries of diversified capsids that upon infection can yield enhanced variants via DNA-driven biopanning. Despite its success in other parvoviruses, this approach has never been performed with bocavirus. Here, I propose to employ shuffling of bocavirus capsids to create new variants with novel tropism.

Dr. Kleopatra RAPTI — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Entwicklung neuartiger immunfluchtfähiger AAVs durch Identifizierung und Mutation immunogener Epitope in den variablen Kapsidregionen des Adeno-assoziierten Virus 9

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

AAVs are small, non-pathogenic viruses of the Parvoviridae family, predominantly isolated from human and primate tissues. Due to their unique properties, such as tropism for specific tissues, low toxicity and low immunogenicity, AAV vectors have been evaluated extensively in animal models and in humans for treatment of a variety of diseases such as hemophilia, ocular and cardiovascular diseases. Despite their efficiency and widespread use in human gene therapy, clinical application is limited by the presence of pre-existing antibodies against the capsid, mainly due to its human origin. In fact, about 50% of patients who could be enrolled in clinical trials have to be excluded due to the presence of antibodies against AAVs. Consequently, there is an urgent need for new experimental strategies permitting the generation of immune-evading AAVs.

Dr. Emre Ufuk KUL — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Entwicklung translationsrelevanter Testplattformen zur Entdeckung neuartiger AAV-Vektoren mit effizienter Transzytose durch die menschliche Blut-Hirn-Schranke

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();

The project develops a practical human-based platform to facilitate the discovery of Adeno-Associated Virus (AAV) capsids with enhanced blood–brain barrier (BBB) penetration and central nervous system (CNS) tropism. This is an early-stage development project that will perform proof-of-principle testing of hiPSC-derived 2D transwell BBB models and immortalized cell line-derived neurovascular unit (NVU) 3D organoids, creating a practical, reproducible, and physiologically relevant system for future high-throughput screening of AAV capsids. The project is two-fold, in that, the testing platform development is supplemented by bioinformatics supported development of designer AAV capsids and leveraging the screening of multiple existing capsid libraries in our laboratory to identify BBB-tropic AAV variants in a human relevant setting. The project will provide a foundation for more translatable CNS gene therapies.

Sharon PORTELLI — Research Project :root { --bg-primary: #f8fafc; --bg-surface: #ffffff; --bg-subtle: #f1f5f9; --text-primary: #0f172a; --text-secondary: #334155; --text-muted: #64748b; --border-light: #e2e8f0; --border-medium: #cbd5e1; --accent-navy: #0f2942; --accent-sky: #0284c7; --shadow-sm: 0 1px 3px rgba(15, 23, 42, 0.04), 0 1px 2px rgba(15, 23, 42, 0.02); --shadow-md: 0 12px 28px -6px rgba(15, 23, 42, 0.07), 0 4px 12px -4px rgba(15, 23, 42, 0.03); --radius-lg: 16px; --transition: all 0.3s cubic-bezier(0.25, 0.8, 0.25, 1); } * { box-sizing: border-box; margin: 0; padding: 0; } body { font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif; background-color: var(--bg-primary); color: var(--text-primary); line-height: 1.65; -webkit-font-smoothing: antialiased; padding: 3.5rem 1.5rem 4rem; } main { max-width: 820px; margin: 0 auto; } .project-card { background: var(--bg-surface); border: 1px solid var(--border-light); border-left: 4px solid var(--accent-sky); border-radius: var(--radius-lg); box-shadow: var(--shadow-sm); transition: var(--transition); overflow: hidden; } .project-card:hover { box-shadow: var(--shadow-md); border-color: var(--border-medium); border-left-color: var(--accent-sky); } .card-header { width: 100%; text-align: left; background: transparent; border: none; padding: 1.75rem 2rem; cursor: pointer; display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; font-family: inherit; } .card-header:focus-visible { outline: 2px solid var(--accent-sky); outline-offset: -2px; } .header-identity { display: flex; align-items: flex-start; gap: 1.35rem; flex: 1; } .researcher-photo-wrap { width: 72px; height: 72px; border-radius: 50%; flex-shrink: 0; overflow: hidden; border: 2px solid #ffffff; box-shadow: 0 4px 12px rgba(15, 23, 42, 0.12); background: linear-gradient(135deg, #0284c7, #0f2942); display: flex; align-items: center; justify-content: center; color: #ffffff; font-family: 'Cormorant Garamond', Georgia, serif; font-weight: 700; font-size: 1.35rem; } .researcher-photo-wrap img { width: 100%; height: 100%; object-fit: cover; object-position: center 20%; display: block; } .card-title-block { flex: 1; } .researcher-name { display: block; font-size: 0.92rem; font-weight: 600; color: var(--accent-sky); letter-spacing: 0.01em; margin-bottom: 0.35rem; } .project-title { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.35rem; font-weight: 700; line-height: 1.25; color: var(--text-primary); margin-bottom: 0.55rem; } .project-teaser { font-size: 0.94rem; color: var(--text-muted); line-height: 1.6; } .project-card.open .project-teaser { display: none; } /* Accordion Animation */ .card-body-wrapper { display: grid; grid-template-rows: 0fr; transition: grid-template-rows 0.36s cubic-bezier(0.25, 0.8, 0.25, 1); } .project-card.open .card-body-wrapper { grid-template-rows: 1fr; } .card-body-inner { overflow: hidden; } .project-body { padding: 1.5rem 2rem 2rem calc(2rem + 72px + 1.35rem); border-top: 1px solid var(--border-light); } .abstract-label { font-family: 'JetBrains Mono', monospace; font-size: 0.72rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 1rem; display: flex; align-items: center; gap: 0.75rem; } .abstract-label::after { content: ""; flex: 1; height: 1px; background: var(--border-light); } .abstract-text p { font-size: 0.98rem; line-height: 1.82; color: var(--text-secondary); margin-bottom: 1.15rem; text-align: justify; hyphens: auto; } .abstract-text p:last-child { margin-bottom: 0; } .abstract-text ul { margin: 0.75rem 0 1.15rem 1.5rem; color: var(--text-secondary); font-size: 0.98rem; } .abstract-text li { margin-bottom: 0.4rem; line-height: 1.7; } @media (max-width: 720px) { body { padding: 2rem 1rem 3rem; } .card-header { flex-direction: column; padding: 1.35rem; } .header-identity { flex-direction: column; gap: 0.9rem; } .project-body { padding: 1.25rem 1.35rem 1.65rem; } } /* Sabrina Weis: einheitlicher dunkelgrüner Akzent */ .researcher-name { color: #14532d !important; } .project-card { border-left-color: #14532d !important; } .project-card:hover { border-left-color: #14532d !important; }
Project Description

Aufklärung der intrazellulären Dynamik von Bocavirus-Vektoren und der intrazellulären Hindernisse, die den Transport und damit die Transduktionseffizienz beeinträchtigen

(function () { const card = document.getElementById('projectCard'); const headerBtn = document.getElementById('toggleHeader'); headerBtn.addEventListener('click', function () { const isOpen = card.classList.toggle('open'); headerBtn.setAttribute('aria-expanded', String(isOpen)); }); })();
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.